University Hospital of Wales
Cardiff, United Kingdom
21 recruiting
Showing 1–20 of 50 trials
Recruiting
Not Applicable
Protocolized Reduction of Non-resuscitation Fluids Versus Usual Care in Septic Shock Patients
Septic Shock
Region Skane1,850 enrolled22 locationsNCT06140147
Recruiting
Phase 3
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Carcinoid TumorCarcinoid Tumor of PancreasCarcinoid Tumor of Liver+6 more
Crinetics Pharmaceuticals Inc.141 enrolled51 locationsNCT07087054
Recruiting
Phase 4
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
C3 Glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Swedish Orphan Biovitrum150 enrolledNCT07746895
Recruiting
Phase 2
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
InfectionsAcute Respiratory Distress Syndrome
BioAegis Therapeutics Inc.600 enrolled70 locationsNCT05947955
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Diabetes Mellitus, Type 1
Eli Lilly and Company300 enrolled136 locationsNCT07222332
Recruiting
Phase 1
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Huntington’s Disease
Sarepta Therapeutics, Inc.32 enrolled2 locationsNCT07536061
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Hemophilia A
Hoffmann-La Roche360 enrolled12 locationsNCT07416604
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Hemophilia A
Hoffmann-La Roche126 enrolled2 locationsNCT07416526
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Diabetes Mellitus, Type 1
Eli Lilly and Company150 enrolled110 locationsNCT07222137
Recruiting
Phase 1Phase 2
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
LymphomaMetastatic Solid TumorsLocally Advanced Solid Tumors+1 more
Turning Point Therapeutics, Inc.75 enrolled68 locationsNCT04094610
Recruiting
Phase 3
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Acute Myeloid Leukemia, Adult
Stichting Hemato-Oncologie voor Volwassenen Nederland448 enrolled201 locationsNCT06652438
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Acute Leukemia
Janssen Research & Development, LLC420 enrolled102 locationsNCT04811560
Recruiting
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
The Leeds Teaching Hospitals NHS Trust550 enrolled71 locationsNCT06557798
Recruiting
Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Multiple Myeloma
Pfizer893 enrolled90 locationsNCT05020236
Recruiting
Phase 3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Multiple Myeloma
Pfizer1,116 enrolled127 locationsNCT05623020
Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb1,700 enrolled99 locationsNCT05489705
Recruiting
Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Progressive Multiple Sclerosis
Hoffmann-La Roche360 enrolled103 locationsNCT07282574
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
Frontotemporal DementiaFTDDementia, Frontotemporal+1 more
AviadoBio Ltd18 enrolled19 locationsNCT06064890
Recruiting
Phase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.160 enrolled138 locationsNCT05667142
Recruiting
Phase 3
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Neutropenia
X4 Pharmaceuticals176 enrolled114 locationsNCT06056297